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Summary
One of the hallmarks of type 2 diabetes is that pancreatic b cells fail to release sufficient amounts of insulin in the presence of
elevated blood glucose levels. Insulin secretion ismodulated bymany hormones and neurotransmitters including acetylcho-
line, the major neurotransmitter of the peripheral parasympathetic nervous system. The physiological role of muscarinic
acetylcholine receptors expressed by pancreatic b cells remains unclear at present. Here, we demonstrate that mutant
mice selectively lacking the M3 muscarinic acetylcholine receptor subtype in pancreatic b cells display impaired glucose
tolerance and greatly reduced insulin release. In contrast, transgenic mice selectively overexpressing M3 receptors in pan-
creatic b cells show a profound increase in glucose tolerance and insulin release. Moreover, thesemutant mice are resistant
to diet-induced glucose intolerance and hyperglycemia. These findings indicate that b cell M3 muscarinic receptors play
a key role in maintaining proper insulin release and glucose homeostasis.Introduction
One characteristic pathophysiological feature of type 2 diabetes
is that glucose fails to stimulate adequate release of insulin from
pancreatic b cells (Kahn, 1994, 2001; Moller, 2001). Glucose-de-
pendent insulin secretion is modulated by several neurotrans-
mitters released from peripheral autonomic nerves (Satin and
Kinard, 1998; Ahren, 2000; Gilon and Henquin, 2001). The major
neurotransmitter of the peripheral parasympathetic nervous
system, acetylcholine, is known to facilitate the release of insulin
in a glucose-dependent fashion (Ahren, 2000; Gilon and Hen-
quin, 2001). This activity has been shown to be mediated by
activation of muscarinic acetylcholine receptors located on the
pancreatic b cells (Satin and Kinard, 1998; Ahren, 2000; Gilon
and Henquin, 2001).
Food intake is known to trigger an increase in efferent para-
sympathetic outflow involving signals of different origins that
are integrated in the brain (Niijima, 1989; Gilon and Henquin,
2001). Acetylcholine is released from intrapancreatic parasym-
pathetic (vagal) nerve endings during the preabsorptive and,
most likely, also during the absorptive phase of feeding (Ahren,
2000; Gilon and Henquin, 2001). At present, the importance
of the parasympathetic innervation of the endocrine pancreas
in the maintenance of normal glucose homeostasis remains
controversial (Ahren, 2000; Gilon and Henquin, 2001). Much of
this controversy is thought to arise from the fact that peripheral
parasympathetic (vagal) nerves release at least five differentCELL METABOLISM 3, 449–461, JUNE 2006 ª2006 ELSEVIER INC. Dneurotransmitters (Ahren, 2000; Gilon and Henquin, 2001) and
that increased parasympathetic outflow does not only affect
the function of the endocrine pancreas but also that of many
other organs and tissues that have important metabolic func-
tions (Hoffman and Taylor, 2001; Wess, 2004).
The administration of atropine and other muscarinic antago-
nists has also led to conflicting results regarding the potential
role of muscarinic receptors in the regulation of insulin release
and glucose homeostasis (Ahren, 2000; Gilon and Henquin,
2001). These agents are known to block all five muscarinic
receptor subtypes (M1–M5) which are widely expressed, in
a complex, overlapping pattern, in many peripheral tissues and
most brain regions (Caulfield and Birdsall, 1998; Wess, 1996,
2004). As a result, the in vivo metabolic effects of muscarinic
antagonists are the sum of a multitude of activities involving
many different tissues and receptor subtypes. For example, it
is well known that atropine impairs the function of essentially
all endocrine and exocrine glands and all smooth muscle organs
and modulates a very large number of central functions (Caulfield
and Birdsall, 1998; Wess, 1996, 2004).
Thus, the present study was designed to assess the impor-
tance of b cell muscarinic acetylcholine receptors in glucose
homeostasis and insulin release in vivo. Specifically, we focused
on the potential metabolic role of the M3 muscarinic receptor
subtype which represents the major muscarinic receptor that
is functional in pancreatic b cells (Henquin and Nenquin, 1988;
Ahren, 2000; Gilon and Henquin, 2001; Duttaroy et al., 2004;OI 10.1016/j.cmet.2006.04.009 449
A R T I C L EFigure 1. Targeted disruption of the mouse M3 muscarinic receptor gene
A) Structures of the WT M3 muscarinic receptor allele, gene targeting vector, targeted allele, and Cre-modified locus. The M3 receptor coding region is represented by the
filled box. The approximate location of the probes (filled bars) and primers (arrows) used for Southern analysis and PCR genotyping studies, respectively, are indicated.
Abbreviations are as follows: E, EcoRV; S, SmaI; X, XhoI.
B) Southern blot analysis of EcoRV-digested genomic DNA from three properly targeted ES cell clones (1, 2, and 5). The 13 kb band indicates the presence of the WT M3
receptor allele (both panels), whereas the 6 kb band (upper panel) and the 3 kb band (lower panel) are diagnostic for the proper integration of the targeting construct.450 CELL METABOLISM : JUNE 2006
Roles for b cell M3 muscarinic receptors in vivoZawalich et al., 2004). M3 receptors are not only expressed by
pancreatic b cells but are present in essentially all glandular
and smooth muscle tissues and most regions of the CNS (Levey
et al., 1994; Eglen et al., 1996; Caulfield and Birdsall, 1998;
Wess, 2004).
To assess the physiological role of b cell M3 muscarinic recep-
tors in the regulation of glucose homeostasis and insulin release
in vivo, we employed Cre/loxP technology to generate mutant
mice lacking M3 receptors in pancreatic b cells only. We antici-
pated that this strategy would eliminate potential confounding
factors caused by the widespread distribution of M3 receptors.
Moreover, to study the metabolic effects of enhanced signaling
through b cell M3 muscarinic receptors, we also generated mu-
tant mice selectively overexpressing M3 muscarinic receptors in
pancreatic b cells.
We found that the absence of b cell M3 muscarinic receptors
led to glucose intolerance and significantly reduced plasma in-
sulin levels. On the other hand, mice that selectively overex-
pressed M3 muscarinic receptors in pancreatic b cells showed
a pronounced increase in glucose tolerance and enhanced
plasma insulin levels. Strikingly, these mutant mice were resis-
tant to diet-induced glucose intolerance and hyperglycemia.
Our findings indicate that b cell M3 muscarinic receptors play
a key role in maintaining proper insulin release and glucose
homeostasis in vivo.
Results
Generation of b cell-specific M3 muscarinic receptor
knockout mice
To generate b cell-specific M3 muscarinic receptor knockout
(KO) mice (b-M3-KO mice) (also referred to as Cre fl/fl mice;
‘‘fl’’ stands for ‘‘floxed’’ indicating that the M3 receptor coding
sequence was flanked by loxP sites; Figure 1A), we crossed mu-
tant mice carrying the ‘‘floxed’’ M3 receptor gene with trans-
genic mice expressing Cre recombinase under the control of
the rat insulin promoter II (RIP-Cre mice; Postic et al., 1999).
The structure of the targeting construct used to generate floxed
M3 receptor mutant mice is shown in Figure 1A. The proper ge-
nomic integration of the targeting vector was verified by PCR
and Southern blot analysis (Figures 1A and 1B).
To generate b-M3-KO mice (Cre fl/fl mice), we crossed fl/+
mice with fl/+ mice that were hemizygous for the RIP-Cre trans-
gene. This mating strategy also produced three littermate con-
trol groups, fl/fl, +/+, and +/+ Cre mice. All mice were born at
the expected Mendelian frequency, and the body weight of
the b-M3-KO mice did not differ significantly from that of theCELL METABOLISM : JUNE 2006three control groups (data not shown). Moreover, b-M3-KO
mice were fertile and showed no obvious developmental, be-
havioral, or morphological deficits.
To assess the efficiency of Cre-mediated deletion of the M3
receptor gene, we employed a PCR strategy using DNA pre-
pared from isolated islets of b-M3-KO mice and the three litter-
mate control groups (Figure 1C; see Figure 1A for the location of
the PCR primers). As shown in Figure 1A, PCR primers 1 and 2
were predicted to yield a 290 bp band only following complete
Cre-mediated excision of the M3 receptor gene. As expected,
use of this primer pair resulted in a 290 bp band only in the
case of islet DNA isolated from b-M3-KO mice (Figure 1C).
PCR primers 3 and 4 which anneal to the 30-untranslated region
of the M3 receptor gene still gave a weak 720 bp signal using
islet DNA from b-M3-KO animals as a template, indicative of
the presence of some nonrecombined M3 muscarinic receptor
gene. This remaining M3 receptor signal may be due to the pres-
ence of genomic DNA derived from non-b islet cells, including
cells producing glucagon, somatostatin, and pancreatic poly-
peptide (Kulkarni et al., 1999).
To confirm the absence of M3 receptor protein in islets from
b-M3-KO mice, we used a previously developed immunoprecip-
itation strategy (Yamada et al., 2001). This strategy involved
the labeling of all muscarinic receptors by the non-subtype-
selective muscarinic antagonist, [3H]quinuclidinyl benzilate
([3H]QNB), followed by selective immunoprecipitation of M3 re-
ceptors by an M3 receptor-specific antiserum (Yamada et al.,
2001). This analysis demonstrated that M3 receptor expression
was dramatically reduced (by w80%) in islets from b-M3-KO
mice (Figure 1D). In contrast, islets derived from the three control
groups showed similar M3 receptor expression levels
(Figure 1D). All four analyzed mouse strains (b-M3-KO mice
and the three littermate control strains) exhibited similar M3
receptor expression levels in the hypothalamus and cerebral
cortex (Figure 1D), two brain regions where M3 receptors are ex-
pressed at relatively high levels (Yamada et al., 2001). The rela-
tively small number of islet M3 receptors remaining in b-M3-KO
mice may be due to the presence of M3 muscarinic receptors
expressed by non-b islet cells (Ahren, 2000; Gilon and Henquin,
2001; Duttaroy et al., 2004) and/or incomplete excision of the M3
receptor gene in b cells. Because of the low expression levels of
M3 receptors in mouse pancreatic b cells (<2 fmol/100 islets; see
below), combined with the lack of highly sensitive M3 receptor-
selective antibodies, we were unable to distinguish between
these two possibilities. In fact, previous studies suggest that
a small population of b cells may escape Cre-mediated recom-
bination following mating of Rip-Cre transgenic mice withC) PCR analysis of genomic DNA prepared from islets of the indicated M3 receptor genotypes (see text for details).
D) Immunoprecipitation of M3 muscarinic receptors from mouse pancreatic islets, hypothalamus, and cerebral cortex. For these studies, 3-month-old littermates of the
indicated M3 receptor genotypes were used. [
3H]QNB-labeled M3 receptors were immunoprecipitated with an M3 receptor-specific antiserum (Yamada et al., 2001), as
described in the Experimental Procedures. Absolute receptor densities for M3 +/+ mice were (fmol/mg protein): islets, 5.6 6 0.2; hypothalamus, 31.2 6 1.1; cortex,
38.9 6 1.2. Data are given as means 6 SEM of at least three independent experiments. **p < 0.01, as compared to the corresponding +/+ value.
E)Analysis of M1 and M3 receptor mRNA expression levels in pancreatic islets. Real-time quantitative RT-PCR studies were carried out using total RNA prepared from islets
of b-M3-KO mice and control (fl/fl) littermates (12 weeks old; n = 4 per group). For details, see Experimental Procedures and Supplemental Data. **p < 0.01 versus control.
F) Carbachol-mediated inositol phosphate (IP) production. IP levels (in cpm) were normalized by glycerophosphoinositol levels (in cpm) which are not affected by the
addition of carbachol and can be considered a measure of tissue amount per well (Berridge et al., 1983). Data are given as means 6 SEM from three independent exper-
iments. *p < 0.05, as compared to the corresponding control (fl/fl) value.
G and H) In vitro insulin release studies. Isolated pancreatic islets prepared from b-M3-KO mice and control (+/+) littermates ([G], 4-month-old males; [H], 11-month-old
males) were incubated for 1 hr at 37ºC in Krebs solution containing the indicated glucose concentrations, either in the absence of ligands or in the presence of the
muscarinic agonist, oxotremorine-M (Oxo-M, 0.5 mM) (G), or GLP-1 (0.1 mM) (H). The amount of insulin secreted into the medium during the 1 hr incubation period was
normalized to the total insulin content of each well (islets plus medium). Data are expressed as means 6 SEM of three independent experiments, each carried out in
triplicate. *p < 0.05, **p < 0.01, as compared to the corresponding WT value.451
A R T I C L Emutant mice carrying a floxed gene (Postic et al., 1999; Crabtree
et al., 2003).
These observations indicate that genomic incorporation of the
loxP sites (including the neo selection cassette) had no signifi-
cant effect on M3 receptor expression levels and that b-M3-
KO mice selectively lacked M3 receptors in pancreatic islets
(b cells).
The M3 receptor, like the M1 and M5 muscarinic receptor sub-
types, is selectively coupled to G proteins of the Gq family (Wess,
1996; Caulfield and Birdsall, 1998). Real-time quantitative
RT-PCR studies showed that the dramatic reduction of M3 re-
ceptor mRNA levels observed with islets from b-M3-KO mice
had no significant effect on M1 receptor expression levels
(Figure 1E). We were unable to detect M5 receptor mRNA in islets
from b-M3-KO and control mice (also see Duttaroy et al., 2004).
Islets from b-M3-KO mice display pronounced deficits in
muscarinic agonist-induced inositol phosphate
production and insulin release
To examine whether the lack of b cell M3 receptors led to im-
paired signaling at the molecular level, we measured the ability
of the muscarinic agonist, carbachol, to stimulate inositol phos-
phate (IP) production in isolated islets prepared from b-M3-KO
mice and control littermates. This analysis showed that carba-
chol-mediated PI hydrolysis was greatly reduced in islets
obtained from b-M3-KO mice (Figure 1F).
Morphometric analysis indicated that b cell mass and the av-
erage size and number of pancreatic islets were not significantly
affected by the lack of b cell M3 muscarinic receptors (Table S1
in the Supplemental Data available with this article online). Pre-
vious in vitro studies demonstrated that stimulation of pancre-
atic (b cell) M3 muscarinic receptors leads to a significant aug-
mentation of glucose-dependent insulin release (Duttaroy
et al., 2004; Zawalich et al., 2004). To confirm that islets pre-
pared from b-M3-KO mice were deficient in this activity, we car-
ried out a series of in vitro insulin release studies using isolated
islets prepared from wild-type (WT, +/+) and b-M3-KO litter-
mates. Oxotremorine-M (Oxo-M), a non-subtype-selective, hy-
drolytically stable muscarinic agonist, was used as a muscarinic
stimulant throughout all experiments. In the presence of a low
concentration of glucose (3.3 mM), Oxo-M (0.5 mM) had no ef-
fect on insulin release in islets from either WT or b-M3-KO
mice (Figure 1G). However, in the presence of a high concentra-
tion of glucose (16.7 mM), Oxo-M (0.5 mM) treatment of WT islets
led to a pronounced increase in glucose-dependent insulin
release (Figure 1G). In striking contrast, the insulin release-
enhancing activity of Oxo-M was dramatically reduced in islets
prepared from b-M3-KO mice (Figure 1G). In the absence of
Oxo-M, glucose (16.7 mM) also released w50% less insulin in
islets from b-M3-KO mice than in islets from WT mice
(Figure 1G). The molecular mechanisms underlying this deficit
remain unclear at present. The total insulin content of islets pre-
pared from b-M3-KO mice was similar to that of WT islets (ng
insulin per islet: b-M3-KO, 120.4 6 16.4; WT, 117.1 6 15.7;
means 6 SEM of three independent experiments), indicating
that the deficits in insulin release observed with islets from
b-M3-KO mice were not due to reduced insulin synthesis or stor-
age. Additional control experiments showed that glucagon-like
peptide-1 (GLP-1; 0.1 mM), an agent which is able to enhance
glucose-dependent insulin release in a fashion similar to acetyl-
choline (Doyle and Egan, 2001), released similar amounts of in-452sulin in islets from b-M3-KO and control mice in the presence of
16.7 mM glucose (Figure 1H). This observation suggested that
the lack of b cell M3 receptors did not result in a generalized im-
pairment in islet function. In sum, these data clearly indicate that
glucose-dependent muscarinic stimulation of insulin release is
greatly reduced in islets from b-M3-KO mice, consistent with
the pronounced reduction in the number of islet M3 muscarinic
receptors found with these mutant mice (Figure 1D).
b-M3-KO mice display impaired glucose tolerance
and insulin release in vivo
Unless stated otherwise, all physiological measurements were
carried out with male mice (littermates) that were 4–6 months
old. As shown in Table 1, the fed and fasting blood glucose and
fed serum insulin levels of b-M3-KO mice did not differ signifi-
cantly from the corresponding values obtainedwith the three con-
trol strains. b-M3-KO mice showed a clear trend toward reduced
fasting serum insulin levels; however, this decrease failed to reach
statistical significance in this set of experiments (p > 0.05).
To examine whether b-M3-KO mice showed deficits in glu-
cose tolerance, we carried out oral and intraperitoneal (i.p.) glu-
cose tolerance tests (OGTT and IGTT, respectively). Following
glucose administration (2 mg/g body weight), the b-M3-KO
mice showed significantly higher blood glucose levels than the
three control strains (+/+, +/+ Cre, and fl/fl) in both OGTT and
IGTT (Figures 2A and 2C). Since the three control strains gave
similar responses (this is also true for all other physiological
studies described below), the data obtained with these three
strains were pooled for the sake of clarity.
To investigate whether the impairment in glucose tolerance
displayed by the b-M3-KO mice in the OGTT and IGTT were
accompanied by deficits in insulin release, we also monitored
serum insulin levels after oral or i.p. administration of glucose
(2 mg/g). b-M3-KO mice showed significantly lower serum insu-
lin levels during the first 60 min after glucose administration
(OGTT) or during the entire 2 hr observation period (IGTT), re-
spectively, as compared to the corresponding control litter-
mates (Figures 2B and 2D). Consistent with this observation,
C-peptide levels were also found to be significantly lower in
b-M3-KO mice throughout the entire 2 hr observation period
following i.p. administration of glucose (2 mg/g; Figure S1A).
To study the degree of insulin sensitivity of the b-M3-KO mice
and their control littermates, we injected mice with a fixed dose
of insulin (0.75 U/kg i.p.) and monitored the resulting decreases
Table 1. Glucose and insulin levels in fl/fl Cre mice (b-M3-KO mice) and control
littermates
+/+ +/+ Cre fl/fl fl/fl Cre
Blood glucose
(fed, mg/dl)
136 6 5 122 6 5 129 6 6 125 6 3
Blood glucose
(fasted, mg/dl)
115 6 9 111 6 16 96 6 8 95 6 4
Serum insulin
(fed, ng/ml)
1.03 6 0.16 1.66 6 0.27 1.39 6 0.22 1.16 6 0.11
Serum insulin
(fasted, ng/ml)
0.83 6 0.22 0.72 6 0.44 1.07 6 0.11 0.52 6 0.21
Measurements were carried out with 16- to 20-week old male littermates (n = 6 per
genotype). The fed and fasting blood glucose and serum insulin levels of the fl/fl
Cre (b-M3-KO) mice did not differ significantly from the corresponding control
values (p > 0.05).CELL METABOLISM : JUNE 2006
Roles for b cell M3 muscarinic receptors in vivoFigure 2. Physiological analysis of b-M3-KO mice and control littermates
A and B) Blood glucose (A) and serum insulin (B) levels following application of an oral dose of glucose (2 mg/g; OGTT; 24-week-old male littermates).
C and D) Blood glucose (C) and serum insulin (D) levels following i.p. administration of glucose (2 mg/g; IGTT; 16-week-old male littermates).
E) Insulin tolerance test (ITT). Blood glucose levels were measured at the indicated time points following i.p. administration of insulin (0.75 U/kg; 20-week-old male mice).
The three control strains (+/+, +/+ Cre, and fl/fl) gave similar results. The data obtained with the three control strains were therefore pooled for the sake of clarity. Data are
expressed as means 6 SEM (b-M3-KO, n = 6; control, n = 15–18). *p < 0.05, **p < 0.01, as compared to the corresponding control value.in blood glucose levels. In these experiments, b-M3-KO mice
showed a reduction in blood glucose levels that was very similar
to that displayed by the corresponding control littermates
(Figure 2E), indicating that the lack of b cell M3 muscarinic re-
ceptors has no significant effect on insulin sensitivity.
Pancreata from adult b-M3-KO mice and control (fl/fl) litter-
mates did not differ significantly in weight (control, 278 6 10
mg, n = 12; b-M3-KO, 2506 18 mg; n = 9) and contained similar
amounts of insulin (mg/pancreas: control, 343 6 19, n = 12;
b-M3-KO, 302 6 14; n = 9).
Real-time quantitative RT-PCR studies using total RNA pre-
pared from islets of b-M3-KO and control (fl/fl) littermates
showed that the relative lack of b cell M3 receptors had no sig-
nificant effect on GLUT2 and insulin mRNA expression levels.
We noted a small increase (w1.6-fold) in glucagon and glucoki-
nase mRNA levels (Figure S2) in islet RNA samples preparedCELL METABOLISM : JUNE 2006from b-M3-KO mice. However, plasma glucagon levels were
not significantly different in b-M3-KO and control (fl/fl) littermates
(b-M3-KO, 78.8 6 8.1 pg/ml, n = 8; control, 62.0 6 5.4 pg/ml;
n = 11; 32-week-old freely fed males).
Generation of transgenic mice selectively
overexpressing M3 muscarinic receptors
in pancreatic b cells
The analysis of b-M3-KO mice indicated that the activity of en-
dogenous b cell M3 muscarinic receptors plays a critical role
in mediating glucose-dependent insulin release and maintaining
proper glucose tolerance. We therefore speculated that en-
hanced signaling through b cell M3 muscarinic receptors might
facilitate glucose-dependent insulin release and lead to im-
proved glucose tolerance. To test this hypothesis, we generated
transgenic mice that selectively overexpressed M3 muscarinic453
A R T I C L Ereceptors in pancreatic b cells. To ensure that M3 receptors
were selectively expressed by pancreatic b cells, transgene ex-
pression was placed under the control of a 0.65 kb fragment of
the rat insulin promoter II (Vasavada et al., 1996; Postic et al.,
1999; Kulkarni et al., 1999).
To be able to distinguish overexpressed M3 receptors from
endogenous M3 receptors, the transgenically expressed M3 re-
ceptors contained two modifications, an N-terminal 9 amino
acid hemagglutinin epitope tag and a deletion of the central por-
tion of the third intracellular loop (amino acids 274–469). Previ-
ous studies have shown that these modifications have no signif-
icant effect on the ligand binding and G protein coupling
properties of the M3 muscarinic receptor (Scho¨neberg et al.,
1995; Maggio et al., 1996). By using standard transgenic tech-
niques (see ‘‘Experimental procedures’’), we obtained several
mutant mouse lines that had incorporated the M3 receptor trans-
gene into their genomes.
To quantify the number of M3 receptors overexpressed in
pancreatic islets (b cells) of the different transgenic lines, we
incubated membranes prepared from pancreatic islets with
a saturating concentration (2 nM) of the non-subtype-selective
muscarinic antagonist,[3H]N-methylscopolamine ([3H]NMS).
Control experiments with nontransgenic WT littermates showed
that endogenous islet muscarinic receptors were expressed at
relatively low levels (w1.6 6 0.2 fmol/100 islets; n = 7). In con-
trast, islets from one of the analyzed transgenic lines, hereafter
referred to as b-M3-Tg1, showed a pronounced increase in islet
muscarinic receptor density (506 2 fmol/100 islets; n = 3). Thus,
assuming that the majority of islet muscarinic receptors repre-
sent b cell M3 receptors (Ahren, 2000; Gilon and Henquin,
2001; Duttaroy et al., 2004; Zawalich et al., 2004), the b-M3-
Tg1 line expressed at least 30-fold more b cell M3 receptors
than the corresponding WT control mice.
RT-PCR studies using total RNA prepared from several pe-
ripheral and central tissues from b-M3-Tg1 mice confirmed
that expression of the M3 receptor transgene could be easily de-
tected using cDNA derived from pancreatic islets (b cells;
Figure 3A). In contrast, expression of the M3 receptor transgene
remained undetectable in other peripheral tissues and in the hy-
pothalamus (Figure 3A). A very faint transgene-specific RT-PCR
signal was observed with cDNA derived from cerebral cortex
(Figure 3A).
Islets from b-M3-Tg1 mice display enhanced muscarinic
agonist-induced IP production and insulin release
To determine whether overexpression of b cell M3 receptors led
to enhanced signaling at the molecular level, we measured the
ability of carbachol to stimulate IP production in isolated islets
prepared from b-M3-Tg1 mice and WT littermates. We found
that carbachol-mediated PI hydrolysis was greatly enhanced
in islets obtained from b-M3-Tg1 mice (Figure 3B). Moreover,
basal IP production was also significantly increased in islets
from b-M3-Tg1 mice (Figure 3B), consistent with previous find-
ings that increasing the density of G protein-coupled receptors
often leads to some degree of ligand-independent G protein
activation (Seifert and Wenzel-Seifert, 2002).
In agreement with the outcome of the IP assays, in vitro insulin
release studies carried out in the presence of 16.7 mM glucose
indicated that the Oxo-M-mediated (0.5 mM) increase in insulin
release was significantly greater in islets obtained from b-M3-
Tg1 mice, as compared to islets from WT littermates (Figure 3C).454b-M3-Tg1 mice exhibit hypoglycemia, hyperinsulinemia,
and greatly increased glucose tolerance
b-M3-Tg1 appeared healthy and showed no obvious behavioral
or morphological abnormalities. Moreover, the body weight of b-
M3-Tg1 mice did not differ significantly from that of their WT lit-
termates when mice were fed standard mouse chow (Figure 5A).
In striking contrast, b-M3-Tg1 mice displayed anw35% reduc-
tion in blood glucose levels in both the fed and fasting state
(Figure 4A; 14-week-old males). The hypoglycemia phenotype
displayed by the b-M3-Tg1 mice was accompanied by anw3-
fold increase in fed and fasting serum insulin levels (Figure 4B;
14-week-old males). Plasma glucagon levels were similar in WT
Figure 3. In vitro studies with b-M3-Tg1 mice and control littermates maintained
on regular mouse chow
A) RT-PCR analysis of M3 receptor transgene expression in tissues from b-M3-Tg1
mice.
RT-PCR studies were carried out as described under Experimental Procedures
(also see text for details). Abbreviations are as follows: G. muscle, gastrocnemius
muscle; BAT, brown adipose tissue; Hypo, hypothalamus; RT, reverse transcrip-
tase.
B) Carbachol-mediated inositol phosphate (IP) production. IP levels (in cpm) were
normalized by glycerophosphoinositol levels (in cpm), which are not affected by
the addition of carbachol and are considered a measure of tissue amount per
well (Berridge et al., 1983). Data are given as means 6 SEM from three indepen-
dent experiments.
C) In vitro insulin release studies. Isolated pancreatic islets prepared from adult WT
and b-M3-Tg1 littermates were incubated for 1 hr at 37ºC in Krebs solution contain-
ing the indicated glucose concentrations, either in the absence or in the presence
of the muscarinic agonist, oxotremorine-M (Oxo-M, 0.5 mM). The amount of insulin
secreted into the medium during the 1 hr incubation period was normalized to the
total insulin content of each well (islets plus medium). Data are expressed as
means 6 SEM of three independent experiments, each carried out in triplicate.
*p < 0.05, **p < 0.01, as compared to the corresponding WT value.CELL METABOLISM : JUNE 2006
Roles for b cell M3 muscarinic receptors in vivoFigure 4. Physiological analysis of b-M3-Tg1 mice and control littermates maintained on regular mouse chow
A)Fed and fasting blood glucose andB) serum insulin levels ofb-M3-Tg1 mice and their WT littermates. Blood was collected from male littermates that were 14 weeks old (n =
9–12 per group). *p < 0.05, **p < 0.01, as compared to the corresponding WT value. C) Blood glucose and D) serum insulin levels following application of an oral dose of
glucose (2 mg/g; OGTT; 10-week-old males; WT, n = 6 per group). E) Blood glucose and F) serum insulin levels following i.p. administration of glucose (2 mg/g; IGTT;
14-week-old males; WT, n = 10;b-M3-Tg1, n = 11).G) Insulin tolerance test (ITT). Blood glucose levels were measured at the indicated time points following i.p. administration
of insulin (0.75 U/kg; 12-week-old males; WT, n = 7;b-M3-Tg1, n = 7). Data are expressed as means6SEM. *p < 0.05, **p < 0.01, as compared to the corresponding WT value.and b-M3-Tg1 mice (WT, 52.8 6 7.0 pg/ml; b-M3-Tg1, 59.4 6
10.3 pg/ml; 16-week-old freely fed males; n = 10 per group).
To investigate whether the b-M3-Tg1 mice showed changes in
glucose tolerance, we carried out oral and i.p. glucose toleranceCELL METABOLISM : JUNE 2006tests (OGTT and IGTT, respectively; glucose dose: 2 mg/g body
weight). In both OGTT and IGTT, the b-M3-Tg1 mice exhibited
dramatically reduced increases in blood glucose levels through-
out the entire 2 hr observation period (Figures 4C and 4E). On the455
A R T I C L EFigure 5. Physiological analysis of b-M3-Tg1 mice and control littermates maintained on a high-fat diet
A) Body weight of 13-week-old male mice maintained on regular mouse chow or a high-fat diet (n = 7–12 per group).
B) Blood glucose levels (fed state) of male mice maintained on a high-fat diet (n = 6 per group). Mice were put on the high-fat diet when they were 4 weeks old.
C) I.p. glucose tolerance test (IGTT; high-fat diet). Blood glucose levels were measured at the indicated time points following i.p. administration of glucose (2 mg/g;
13-week-old males; WT, n = 9; b-M3-Tg1, n = 7).
D) Serum insulin levels following i.p. administration of glucose (2 mg/g; high-fat diet; 16-week-old males; WT, n = 7; b-M3-Tg1, n = 5).
E) Insulin tolerance test (ITT; high-fat diet). Blood glucose levels were measured at the indicated time points following i.p. administration of insulin (0.75 U/kg; 18-week-old
males; WT, n = 9; b-M3-Tg1, n = 7). Data are expressed as means 6 SEM. **p < 0.01, as compared to the corresponding WT value.other hand, b-M3-Tg1 mice displayed significantly increased se-
rum insulin levels (byw2- tow3-fold as compared to their WT
littermates) during the first 15–30 min after glucose administra-
tion (Figures 4D and 4F). The measurement of plasma C-peptide
levels led to similar results (IGTT; Figure S1B).
Administration of a fixed dose of insulin (0.75 U/kg i.p.)
showed that overexpression of b cell M3 receptors had no signif-
icant effect on insulin sensitivity (12-week-old males; Figure 4G),
indicating that the increase in serum insulin levels displayed by
the b-M3-Tg1 mice was not due to peripheral insulin resistance.
b-M3-Tg1 mice are resistant against diet-induced
hyperglycemia and glucose intolerance
As described in the previous paragraph, b-M3-Tg1 mice showed
a pronounced increase in glucose tolerance, probably due to
enhanced insulin release following glucose administration. It is456well known that the consumption of an energy-rich, high-fat
diet triggers a number of metabolic changes including impaired
glucose tolerance and hyperglycemia. To examine whether the
overexpression of M3 receptors in pancreatic b cells could pre-
vent or reduce the severity of these metabolic deficits, 4-week-
old b-M3-Tg1 mice and their WT littermates were fed a high-fat
diet (fat content: 35.5%, w/w) and then monitored for 9 weeks.
Consumption of the high-fat diet led to significant weight gain
in both WT and b-M3-Tg1 mice, as compared to WT and b-M3-
Tg1 mice maintained on regular mouse chow (Figure 5A). WT
mice consuming the high-fat diet developed hyperglycemia
(Figure 5B). In striking contrast, blood glucose levels of b-M3-
Tg1 mice remained in the normal range during the entire obser-
vation period (Figure 5B). Moreover, after 9 weeks on the high-
fat diet, WT mice showed markedly increased fasting blood
glucose levels and severely reduced glucose tolerance, asCELL METABOLISM : JUNE 2006
Roles for b cell M3 muscarinic receptors in vivoassessed by an i.p. glucose tolerance test (Figure 5C). On the
other hand, at the same point, b-M3-Tg1 littermates exhibited
normal fasting blood glucose levels and glucose tolerance
(Figure 5C). Following the i.p. glucose load, b-M3-Tg1 mice
showed significantly higher serum insulin levels throughout
the entire 2 hr observation period (Figure 5D), suggesting that
the improved glucose tolerance displayed by the b-M3-Tg1
mice maintained on the high fat diet is due to enhanced insulin
release.
Administration of a fixed dose of insulin (0.75 U/kg i.p.) to mice
maintained on the high-fat diet showed that both WT and b-M3-
Tg1 mice displayed a reduction in insulin sensitivity, as com-
pared to WT and b-M3-Tg1 mice consuming standard mouse
chow (compare Figure 5E with Figure 4G). However, blood glu-
cose levels initially declined more rapidly in b-M3-Tg1 than in WT
mice (18-week-old males; Figure 5E).
To exclude the possibility that the pronounced metabolic
changes displayed by the b-M3-Tg1 mutant mice were caused
by a transgene ‘‘integration effect’’, we analyzed another inde-
pendent transgenic mouse line, referred to as b-M3-Tg2, that
showed an at least 8-fold increase in the density of islet (b cell)
M3 receptors (number of islet [
3H]NMS binding sites: 12.5 6
1.1 fmol/100 islets). Analysis of blood glucose levels and glu-
cose tolerance tests showed that b-M3-Tg2 mutant mice ex-
hibited qualitatively similar phenotypical changes as b-M3-Tg1
mice (data not shown). This observation strongly supports the
concept that the pronounced metabolic changes displayed by
the b-M3-Tg1 mice were indeed caused by overexpression of
M3 receptors in pancreatic b cells.
Pancreata from adult b-M3-Tg1 mice and WT littermates did
not differ significantly in weight (WT, 226 6 6 mg, n = 7; b-M3-
Tg1, 2486 9 mg; n = 9) and contained similar amounts of insulin
(mg/pancreas: WT, 284 6 17, n = 7; b-M3-Tg1, 262 6 13, n = 9).
Discussion
The primary focus of this study was to examine the potential im-
portance of b cell M3 muscarinic receptors in maintaining normal
glucose homeostasis and insulin release in vivo. We found that
b-M3-KO mice showed a significant impairment in glucose toler-
ance, independent of the route of glucose administration (intra-
gastric or i.p.; Figures 2A and 2C). This observation clearly indi-
cates that the activity of b cell M3 muscarinic receptors is
essential for maintaining normal glucose homeostasis. This find-
ing also suggests that the glucose-mediated activation of pan-
creatic efferent parasympathetic nerves is not only a transient
phenomenon associated with the vagus-mediated preabsorp-
tive phase of feeding (Ahren, 2000; Gilon and Henquin, 2001),
but represents a rather long-lasting effect that persists through-
out the absorptive phase of feeding.
In agreement with the in vitro insulin release studies
(Figure 1G), we observed that the impairment in glucose toler-
ance displayed by the b-M3-KO mice was accompanied by sig-
nificantly blunted increases in serum insulin levels following an
intragastric or i.p. glucose load in vivo (Figures 2B and 2D).
This observation strongly suggests that glucose-mediated stim-
ulation of efferent parasympathetic nerves triggers the activa-
tion of b cell M3 muscarinic receptors, leading to a long-lasting
increase in pancreatic insulin release that is critical for maintain-
ing normal glucose homeostasis.CELL METABOLISM : JUNE 2006Polymorphisms in the M3 receptor gene that are associated
with type 2 diabetes or impaired glucose tolerance in humans
have not been reported so far. However, given the metabolic
deficits displayed by the b-M3-KO mice, such polymorphisms
may exist.
It has been reported that the RIPII promoter is not only func-
tional in pancreatic b cells but may also have some activity in ce-
rebral cortex and hypothalamus (Gannon et al., 2000; Cui et al.,
2004). However, by using a combined radioligand binding/im-
munoprecipitation strategy which can determine the number
of functional receptors, we found that M3 receptor expression
levels were similar in the hypothalamus and cerebral cortex of
b-M3-KO mice and control littermates (Figure 1D). By crossing
mice heterozygous for the floxed M3 receptor allele (fl/+ mice)
with fl/+ mice that expressed Cre recombinase under the control
of the rat nestin promoter and enhancer (Tronche et al., 1999;
Bru¨ning et al., 2000), we recently generated brain/neuron-spe-
cific M3 receptor KO mice (brain-M3-KO mice). Preliminary stud-
ies showed that these mutant mice displayed normal glucose
tolerance and glucose-induced insulin release (unpublished
data). Taken together, these observations strongly suggest
that the metabolic deficits displayed by the b-M3-KO mice are
not due to reduced central M3 receptor levels.
Ohnuma et al. (1996) showed that intracerebroventricular
(ICV) administration of a muscarinic receptor antagonist
(N-methylatropine) reduced glucose tolerance and blunted glu-
cose-dependent increases in plasma insulin levels in rats. This
observation is consistent with the concept that central musca-
rinic receptors also play a role in regulating neuronal pathways
critical for proper insulin release and glucose homeostasis.
However, given our observations summarized in the previous
paragraph, the metabolic deficits described by Ohnuma et al.
(1996) are most likely due to the blockade of non-M3 or multiple
muscarinic receptor subtypes.
In striking contrast to b-M3-KO mice, whole body M3 receptor
KO mice exhibit a reduction in body weight and body fat mass,
associated with an increase in glucose tolerance and insulin
sensitivity (Yamada et al., 2001; Duttaroy et al., 2004). As dis-
cussed by Yamada et al. (2001), it is likely that these metabolic
changes are primarily due to the fact that whole body M3 recep-
tor KO mice are hypophagic and lean.
Interestingly, isolated islets prepared from b-M3-KO mice
showed a significant reduction in glucose-induced (16.7 mM)
insulin secretion (Figure 1G). To explore the molecular basis
underlying this phenomenon, we carried out a series of addi-
tional experiments. These studies indicated that the reduction
in glucose-induced insulin secretion observed in the absence
of M3 receptors is not due to decreased islet insulin content, re-
duced GLUT2 or glucokinase expression levels, or changes of
an unknown circulatory factor. Moreover, in vitro insulin release
studies using GLP-1 as a secretagogue showed that the lack
of b cell M3 receptors did not result in a generalized impairment
in islet function (Figure 1H). At present, we therefore do not
have a clear explanation for the reduction in glucose-induced in-
sulin secretion displayed by islets prepared from b-M3-KO mice.
One possibility is that the lack of b cell M3 receptors causes
secondary changes in the expression or functional state of
as yet unknown downstream signaling components involved in
glucose-stimulated insulin release.
Given the metabolic deficits displayed by the b-M3-KO mice,
we tested the hypothesis that enhanced signaling through b cell457
A R T I C L EM3 muscarinic receptors might facilitate insulin release leading
to improved glucose tolerance. Specifically, we analyzed a
transgenic mouse line, referred to as b-M3-Tg1, that selectively
overexpressed a modified version of the M3 muscarinic receptor
in pancreatic b cells (Figure 3A).
Strikingly, b-M3-Tg1 mice displayed an w35% reduction in
blood glucose levels in both the fed and fasting state
(Figure 4A), but showed anw3-fold increase in fed and fasting
serum insulin levels (Figure 4B), as compared to their WT litter-
mates. b-M3-Tg1 mice showed similar sensitivity to exoge-
nously administered insulin as their control littermates
(Figure 4G). This observation clearly indicates that the increase
in serum insulin levels displayed by the b-M3-Tg1 mice is not
a secondary effect caused by a state of insulin resistance.
Moreover, b-M3-Tg1 mice showed dramatically reduced in-
creases in blood glucose levels in glucose tolerance tests (Fig-
ures 4C and 4E), accompanied by significantly enhanced eleva-
tions in serum insulin levels (w2- to w3-fold as compared to
their WT littermates; Figures 4D and 4F). The striking metabolic
changes displayed by the b-M3-Tg1 mouse line were also ob-
served with a second transgenic line, b-M3-Tg2, that overex-
pressed b cell M3 receptors at considerably lower levels than
the b-M3-Tg1 mice (data not shown). Taken together, these find-
ings indicate that basal and glucose-dependent insulin release
and glucose tolerance can be greatly enhanced by increasing
the density of b cell M3 receptors.
We also demonstrated that b-M3-Tg1 mice were protected
against diet-induced hyperglycemia and glucose intolerance
(Figures 5B and 5C). Insulin measurements suggested that the
improved glucose tolerance displayed by the b-M3-Tg1 mice
maintained on the high fat diet is most likely due to enhanced
insulin release (Figure 5D).
All data presented in the Results section were obtained with
male mice. To examine whether the major phenotypes dis-
played by the male M3 receptor mutant mice were gender-inde-
pendent, we repeated several key experiments with female
b-M3-KO and b-M3-Tg1 mice (and control littermates). In these
studies, the female mutant mice showed similar phenotypes
as observed with their male counterparts (Tables S2 and S3;
Figure S3), indicating that the important metabolic functions of
b cell M3 receptors are gender-independent.
Our data therefore support the concept that b cell M3 musca-
rinic receptors play a critical role in regulating insulin release and
glucose homeostasis in vivo. The M3 receptor is not only ex-
pressed in pancreatic b cells but is present in many peripheral
and central tissues (Wess, 1996). The activity of the M3 receptor,
like that of other G protein-coupled receptors (GPCRs), is regu-
lated by several other cellular proteins including GPCR kinases
(GRKs), RGS proteins, and various classes of receptor-associ-
ated proteins (Wess, 1996; Bockaert et al., 2004). Future studies
may therefore lead to the development of therapeutic strategies
able to selectively enhance signaling through b cell M3 receptors
by targeting receptor-regulatory proteins that are preferentially
expressed in pancreatic b cells.
Experimental procedures
Generation of mutant mice selectively lacking M3 muscarinic
receptors in pancreatic b cells
A mouse M3 muscarinic receptor genomic clone was isolated from a 129Sv/J
mouse genomic library (Genome Systems; Yamada et al., 2001). To generate458a floxed M3 receptor allele, we created the targeting vector shown in Fig-
ure 1A, which is derived from the pLoxpneo vector (Yang et al., 1998). In
this construct, a PGKneo selection cassette flanked by loxP sites was intro-
ducedw0.45 kb downstream of the polyA signal of the mouse M3 muscarinic
receptor gene. A third loxP sequence, together with a diagnostic EcoRV site,
was introduced into an intronic region,w0.27 bp upstream of the translation
start codon. The targeting vector was linearized by NotI and introduced into
TC1(129SvEv) embryonic stem (ES) cells (Deng et al., 1996) by electropora-
tion. Clones resistant to G418 and gancyclovir were isolated as described
(Yang et al., 1998). The occurrence of homologous recombination was con-
firmed by Southern hybridization (Figures 1A and 1B). Properly targeted ES
cell clones were microinjected into C57BL/6 blastocysts to generate male
chimeric offspring, which in turn were mated with female C57BL/6 mice (Ta-
conic) to generate F1 offspring. F1 animals heterozygous for the floxed M3
receptor allele (fl/+) mice were then crossed to hemizygous transgenic
mice expressing Cre recombinase under the control of the b cell-specific
rat insulin promoter II (RIP-Cre mice; genetic background: C57BL/6; supplier:
The Jackson Laboratories; Postic et al., 1999). The structure of the RIP II
transgene has been described in detail previously (Postic et al., 1999). The
resulting fl/+ Cre and fl/+ mice were then intermated to generate b-M3-KO
mice (Cre fl/fl mice) and the three corresponding littermate control groups,
fl/fl, +/+, and +/+ Cre mice.
Generation of mutant mice selectively overexpressing
M3 muscarinic receptors in pancreatic b cells
A transgene was constructed in which expression of the rat M3 muscarinic
receptor was under the control of a 650 bp fragment of the rat insulin pro-
moter II (RIP II; Vasavada et al., 1996). The transgenic M3 receptor contained
two modifications in order to distinguish it more easily from the endogenous
mouse M3 muscarinic receptor, an N-terminal 9 amino acid hemagglutinin
epitope tag and a deletion of the central portion of the third intracellular
loop (Ala274–Lys469). Previous studies have shown that these modifications
have no significant effect on the ligand binding and functional properties of
the M3 receptor (Scho¨neberg et al., 1995; Maggio et al., 1996). Briefly, the
RIP-M3 transgene was constructed by placing the modified M3 receptor cod-
ing sequence downstream of the 650 bp RIP II fragment and upstream of un-
translated human growth hormone sequences containing transcriptional ter-
mination, polyadenylation, and splicing signals (the vector into which the
modified M3 receptor coding sequence was inserted was kindly provided
by Dr. Adolfo Garcia-Ocana, University of Pittsburgh). The resulting 4.1 kb
transgene was isolated, purified, and microinjected into the pronuclei of
ova prepared from C57BL/6 mice (Taconic). Transgenic mice were identified
by Southern blot analysis of BlgII-digested mouse tail DNA. A 1.36 kb BamHI-
BglII fragment corresponding to most of the 30 untranslated human growth
hormone sequence was used as a probe. Using these procedures, we iden-
tified three founder mice that stably transmitted the transgene to their prog-
eny. From these founder animals, we generated two independent transgenic
mouse lines, referred to as b-M3-Tg1 and b-M3-Tg2. Both lines were main-
tained on a pure C57BL/6 background.
Genotyping studies
b-M3-KO mice and control strains
Mouse genotypes were determined via Southern blotting and/or PCR analy-
sis (Figures 1A and 1B; for details, see Supplemental Data). The presence of
the Cre transgene was detected by using the PCR primers 50-CCTGGAAAA
TGCTTCTGTCCG (forward) and 50-CAGGGTGTTATAAGCAATCCC (reverse;
size of PCR product: 400 bp; PCR conditions, 94ºC for 10 min followed by 32
cycles at 94ºC for 45 s, 54ºC for 30 s, and 68ºC for 45 s).
b-M3-Tg mice
To confirm the presence of the M3 receptor transgene in b-M3-Tg mice, the
following PCR primers which anneal to the 30-untranslated region of the
transgene were used: 50-CTACGGGCTGCTCTACTGCTTCAGG (forward),
50-GGCACTGGAGTGGCAACTTCCAAGG (reverse) (size of PCR product,
171 bp; PCR conditions, 94ºC for 10 min followed by 30 cycles at 94ºC for
30 s, 60ºC for 30 s, and 72ºC for 60 s).
Mouse maintenance and diet
Mice were housed four to five per cage in a specific pathogen-free barrier fa-
cility, maintained on a 12 hr light/dark cycle. Unless indicated otherwise, allCELL METABOLISM : JUNE 2006
Roles for b cell M3 muscarinic receptors in vivoexperiments were carried out with male littermates that were 4–6 months old
at the time of testing.
Mice were fed ad libitum with a standard mouse chow (4% (w/w) fat con-
tent; Zeigler, Gardners, PA). When stated, 4-week-old male mice were put on
a high-fat diet (35.5% (w/w) fat content; # F3282, Bioserv, Frenchtown, NJ)
for 9 weeks.
Islet isolation and in vitro insulin secretion studies
Pancreatic islets were isolated from WT and M3 receptor mutant mice and
prepared for in vitro insulin release studies as described by Saeki et al.
(2002). After purification, islets from b-M3-KO and control mice were incu-
bated for 18–20 hr in RPMI 1640 cell culture medium (Invitrogen/Gibco) sup-
plemented with 5.5 mM glucose, 10% fetal bovine serum, 100 U/ml penicillin,
and 100 mg/ml streptomycin. We noted that islets from b-M3-Tg1 mice re-
leased significant amounts of insulin into the medium during the 18–20 hr in-
cubation step, consistent with previous findings that overexpression of G
protein-coupled receptors can lead to some degree of ligand-independent
signaling (Seifert and Wenzel-Seifert, 2002). For this reason, this incubation
step was omitted when islets from b-M3-Tg1 and WT control mice were
used for insulin secretion studies. Prior to stimulation, islets were preincu-
bated for 1 hr at 37ºC in an oxygenated, modified Krebs solution (composi-
tion in mM: 3.3 glucose, 120 NaCl, 5 KCl, 1.1 MgCl2, 2.6 CaCl2, 25 NaHCO3,
and 0.5% bovine serum albumin; [pH 7.4]). Batches of 10 islets were then in-
cubated in 12-well cell culture plates for 1 hr in a CO2 incubator at 37ºC in the
same solution supplemented with different amounts of glucose and 0.5 mM of
the muscarinic agonist, Oxo-M (Sigma), or 0.1 mM GLP-1 (7–36) amide
(Bachem). All experiments were carried out in triplicate. The medium was col-
lected for insulin measurements, and the remaining islet insulin was
extracted by sonication in acid/ethanol (Davalli et al., 1995). The amount of
insulin secreted during the incubation period was normalized to the total in-
sulin content of each well (islets plus medium). Insulin concentrations were
determined by ELISA (Crystal Chem Inc.).
In vivo physiological studies
Oral and intraperitoneal (i.p.) glucose tolerance tests (OGTT and IGTT, re-
spectively) were carried out with mice that had been subjected to an over-
night (10–12 hr) fast. In the OGTT, mice were administered an oral load of glu-
cose (2 mg/g body weight) via oral gavage. In the IGTT, mice received the
same dose of glucose via i.p. injection. In both tests, blood samples were col-
lected via retroorbital sinus puncture before (0 min) and 15, 30, 60, and 120
min after glucose administration. Blood glucose levels were determined us-
ing an automated blood glucose reader (Glucometer Elite Sensor, Bayer).
Serum insulin concentrations were determined via ELISA (Crystal Chem
Inc.). Plasma glucagon concentrations were measured via radioimmunoas-
say (Linco kit).
For insulin tolerance (sensitivity) tests, human insulin (0.75 U/kg; Eli Lilly)
was administered i.p. to mice that had been fasted overnight for 10–12 hr
(b-M3-KO and control mice) or for 6 hr (b-M3-Tg and WT mice), respectively.
Blood glucose measurements were carried out immediately before and 15,
30, and 60 min after insulin injection. Blood samples were taken from the
tail vein.
Real-time quantitative RT-PCR studies
Total RNA was isolated from pancreatic islets of b-M3-KO mice and control
(fl/fl) littermates (w100–150 islets per mouse) using the RNAqueous-Micro
kit (Ambion) and treated with DNase I for 15 min at room temperature.
Reverse transcription was performed using SuperScript III RT Super Mix
(Invitrogen), and gene expression levels were measured by real-time quanti-
tative RT-PCR (7900HT SDS; Applied Biosystems). PCR reactions (25 ml total
volume) included cDNA (w50 ng of initial RNA sample), 100–120 nM of each
primer, and 12.5 ml of 23 SYBR Green Master Mix (Applied Biosystems). The
PCR cycling conditions were as follows: 50ºC for 2 min, 95ºC for 10 min, and
40 cycles at 95ºC for 15 s, and 60ºC for 1 min, respectively. The expression of
cyclophilin A served as an internal control. Four independent samples pre-
pared from four different mice were used per genotype. PCR reactions
were carried out in triplicate. The results were expressed as fold changes
in expression of a particular RNA transcript relative to cyclophilin A expres-
sion between control and M3 receptor mutant mice (for primer sequences,
see Supplemental Data).CELL METABOLISM : JUNE 2006Carbachol-mediated inositol phosphate (IP) production in isolated
pancreatic islets
Islets prepared from control and M3 receptor mutant mice were incubated for
20 hr in 12-well plates (75 islets/well) in RPMI 1640 cell culture medium (Invi-
trogen/Gibco) supplemented with 5.5 mM glucose, 10% fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin, and 10 mCi/ml of myo-[3H]inosi-
tol (specific activity: 20 Ci/mmol; American Radiolabeled Chemicals Inc.) at
37ºC in a 5% CO2 atmosphere. After this labeling period, islets were washed
five times at room temperature with Krebs-Ringer bicarbonate buffer (120
mM NaCl, 5 mM KCl, 1.1 mM MgCl2, 2.6 mM CaCl2, and 25 mM NaHCO3,
3.3 mM glucose, and 0.5% bovine serum albumin; [pH 7.4]). Islets were
then preincubated in 1 ml of the same buffer containing 10 mM LiCl at
room temperature for 20 min. After the addition of different concentrations
of carbachol, islets were incubated for 1 hr at 37ºC. Reactions were termi-
nated and IP and glycerophosphoinositol levels were determined via anion
chromatography, as described in detail previously (Berridge et al., 1983;
Hamdan et al., 2002).
Radioligand binding studies with membranes prepared from
pancreatic islets
Membranes were prepared from isolated mouse pancreatic islets as de-
scribed (Ahren et al., 1999) and incubated with a saturating concentration
(2 nM) of the non-subtype-selective muscarinic antagonist, [3H]NMS
(specific activity: 83 Ci/mmol; PerkinElmer), essentially as described (Do¨rje
et al., 1991). Binding reactions were carried out for 1 hr at room temperature
(22ºC). Nonspecific binding was determined in the presence of 10 mM
atropine.
Quantification of M3 muscarinic receptor expression levels via an
immunoprecipitation strategy
To quantitate the expression of M3 muscarinic receptor protein in different
mouse tissues, we used a combined radioligand binding/immunoprecipita-
tion strategy (Yamada et al., 2001). Membranes were prepared from mouse
islets and different brain tissues as described (Gautam et al., 2005) and then
incubated for 1 hr at room temperature (22ºC) with a saturating concentration
(2 nM) of the non-subtype-selective muscarinic antagonist, [3H]QNB (specific
activity: 42 Ci/mmol; PerkinElmer). Subsequently, [3H]QNB-labeled M3
receptors were immunoprecipitated by the use of an M3 receptor-specific
rabbit polyclonal antiserum, as described by Yamada et al. (2001). The
amount of [3H]QNB-labeled M3 receptors in the immunoprecipitates was
determined by liquid scintillography.
Determination of pancreatic insulin content
Total pancreatic insulin content was measured by using an acid-ethanol
method, as described in detail previously (Duttaroy et al., 2004). Insulin
concentrations in pancreatic extracts were measured via ELISA (Crystal
Chem Inc.).
RT-PCR analysis of M3 receptor transgene expression
Total RNA was extracted from various peripheral and central tissues of b-M3-
Tg1 mice using the QIAzol Lysis Reagent (Qiagen). The RNA was then
reversed transcribed with MuLV reverse transcriptase, and cDNA was gener-
ated using the GeneAmp RNA PCR kit (Applied Biosystems). The reverse
transcription step was omitted in control samples to test for the presence
of contaminating genomic DNA. The RT products were amplified via PCR
using a primer pair specific for the M3 receptor transgene (M3HA-F, 5
0-CCTA
CGACGTCCCCGACTAC [this primer anneals to the hemagglutinin epitope
tag sequence present at the N terminus of the transgenic construct]; M3-R:
50-TGATGTAGGTCGTGAACAGG) and the following cycling conditions:
94ºC for 3 min followed by 30 cycles at 94ºC for 25 s, 54ºC for 40 s, and
72ºC for 30 s. PCRs were carried out in a final volume of 50 ml containing
2 ml of the RT reaction product (corresponding to w0.1 mg RNA), 5 ml 103
Taq buffer containing 200 mM (NH4)2SO4 (Fermentas), 2 mM MgCl2, 1 mM
of each dNTP, 200 nM of each PCR primer, and 1 unit of recombinant Taq
DNA polymerase (Fermentas). As an internal control, a mouse GAPDH-spe-
cific primer pair (forward, 50-CGTGGAGTCTACTGGTGTCTTCACC, reverse,
50-GATGGCATGGACTGTGGTCATGAGC) was used. The sizes of the RT-
PCR products were: M3 receptor transgene, 405 bp; GAPDH, 258 bp.459
A R T I C L EStatistics
Data are expressed as means 6 SEM for the indicated number of observa-
tions. p values were calculated using one-way analysis of variance followed
by appropriate posthoc tests.
Supplemental data
Supplemental data include Supplemental Experimental Procedures, three
figures, and three tables and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/3/6/449/DC1/.
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